effects of semaglutide on chronic kidney disease 🚨 Journal Club: FLOW Trial Review 🚨 The FLOW Trial, published in The New England Journal Medicine (May 2024), evaluated the of in patients with type Chronic Kidney Disease | Ozempic®

Last month, we shared with you an exciting $250,000 Matching Gift challenge , made possible through the generosity of faithful CMDA partners

The role of adipose tissue in inflammatory bowel diseases

Summary: This study investigated the effects of Cagrilintide alone and in combination with Semaglutide in patients with type 2 diabetes and obesity

Ozempic, known by its generic name semaglutide, has emerged as a significant prescription medication in the management of type 2 diabetes

A typical reported change is small, 1 to 3 kg over a few months, and the data are sparse

However, even with a three medication regimen (RASi, SGLT2i, and nsMRAs), there is still undeniably room for improvement, because residual risk in diabetic still looms large